Is Vulvar Lichen Sclerosus an Autoimmune Disorder?
Yes, vulvar lichen sclerosus is very likely an autoimmune disorder, though the exact pathogenic mechanisms remain incompletely understood.
Evidence Supporting Autoimmune Etiology
The strongest evidence comes from multiple converging lines of investigation:
Clinical Associations with Autoimmune Disease
Autoimmune comorbidities occur in approximately 25-35% of patients with vulvar lichen sclerosus, which is substantially higher than the general population 1, 2. The most common associated conditions include:
- Psoriasis
- Hashimoto's thyroiditis
- Lichen planus
- Vitiligo 1
A large case-control study demonstrated that autoimmune disorders were significantly more frequent in patients with vulvar LS compared to controls (28% vs 9%; P < .001) 2. In children with vulvar LS, autoimmune disease prevalence reaches 24.5%, rising to 34.6% in adults 1.
Immunologic and Molecular Evidence
The molecular signature of vulvar lichen sclerosus demonstrates a clear Th1-mediated autoimmune phenotype 3. Gene expression profiling reveals:
- Significantly increased pro-inflammatory cytokines (IFNγ, CXCR3, CXCL9-11, CCR5, CCL4-5) specific for Th1 IFNγ-induced immune responses
- Pronounced dermal infiltrates of CD4+, CD8+, and FOXP3+ T-cells
- 9.5-fold upregulation of microRNA-155 (miR-155), a key regulator of immune responses 3
This cytotoxic T-lymphocyte infiltration pattern suggests immune-mediated tissue injury consistent with autoimmune pathogenesis 4, 3.
Autoantibody Prevalence
Circulating autoantibodies are present in 31-41% of patients with vulvar lichen sclerosus 1, 2:
- Antinuclear antibodies: 31.0%
- Thyroid peroxidase antibodies: 16.1%
- Thyroglobulin antibodies: 18.9%
- Parietal cell antibodies: 5.3%
- Abnormal thyroid function: 8.2% 1
Important Clinical Implications
Screening Recommendations
Based on the British Association of Dermatologists guidelines, an autoantibody screen is useful only if there are clinical features suggesting an autoimmune disorder 5. However, given the high prevalence of thyroid disease and pernicious anemia, recent evidence supports more proactive screening 1:
Initial autoimmune screening in vulvar LS should include:
- Thyroid stimulating hormone (TSH)
- Vitamin B12 levels
- Intrinsic factor antibodies
- Parietal cell antibodies
- Thyroid antibody testing if hypothyroid 1
Diagnostic Considerations
Premenopausal patients with vulvar LS have significantly higher rates of autoimmune comorbidities (46.7% vs 10.9% in postmenopausal patients; P <0.001) 4. These younger patients also experience longer diagnostic delays (3.9 vs 1.5 years) and less definitive diagnostic terminology on biopsy reports (40% vs 75%), suggesting under-recognition in this population 4.
Important Caveats
Gender Differences in Pathogenesis
The autoimmune hypothesis applies primarily to vulvar lichen sclerosus in women; male genital lichen sclerosus appears to have different pathogenic mechanisms 6. In men, epidemiological data show autoimmune comorbidities occur no more frequently than in the general population, and the urine/occlusion hypothesis (related to foreskin anatomy and urine exposure) appears to be the predominant driver 6.
Heterogeneity of Disease
Recent transcriptomic analyses suggest molecular heterogeneity, with autoimmune mechanisms potentially operative in only a subset of patients 6. This may explain why some patients respond differently to treatment and have varying clinical courses.